FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313256472> ?p ?o ?g. }

• W4313256472 endingPage "144" @default.
• W4313256472 startingPage "135" @default.
• W4313256472 abstract "We compared the efficacy of modified 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) with that of gemcitabine plus nab-paclitaxel (GnP) for locally advanced pancreatic cancer (LAPC).Patients with untreated LAPC were randomly assigned (1:1) to receive mFOLFIRINOX or GnP. One-year overall survival (OS) was the primary endpoint. The major secondary end-points included progression-free survival (PFS), response rate (RR), carbohydrate antigen 19-9 (CA19-9) response, and adverse events. The sample size was 124 patients to select a more effective regimen with a minimum probability of 0.85 and to examine the null hypothesis of the 1-year OS <53%.Of the 126 patients enrolled from 29 institutions, 125 were deemed eligible. The 1-year OS was 77.4% (95% CI, 64.9-86.0) and 82.5% (95% CI, 70.7-89.9) in the mFOLFIRINOX and GnP arms, respectively. The median PFS was 11.2 (95% CI, 9.9-15.9) and 9.4 months (95% CI, 7.4-12.8) in the mFOLFIRINOX and GnP arms, respectively. The RR and CA19-9 response rate were 30.9% (95% CI, 19.1-44.8) and 57.1% (95% CI, 41.0-72.3) and 42.1% (95% CI 29.1-55.9) and 85.0% (95% CI, 70.2-94.3) in the mFOLFIRINOX and GnP arms, respectively. Grade 3-4 diarrhoea and anorexia were predominant in the mFOLFIRINOX arm.GnP was considered the candidate for a subsequent phase III trial because of its better RR, CA19-9 response, and mild gastrointestinal toxicities. Both regimens displayed higher efficacy in the 1-year survival than in the historical data of gemcitabine monotherapy." @default.
• W4313256472 created "2023-01-06" @default.
• W4313256472 creator A5003123255 @default.
• W4313256472 creator A5010319344 @default.
• W4313256472 creator A5015481734 @default.
• W4313256472 creator A5021509769 @default.
• W4313256472 creator A5022537134 @default.
• W4313256472 creator A5024065137 @default.
• W4313256472 creator A5026907664 @default.
• W4313256472 creator A5032994101 @default.
• W4313256472 creator A5033152224 @default.
• W4313256472 creator A5034675205 @default.
• W4313256472 creator A5036817380 @default.
• W4313256472 creator A5040581923 @default.
• W4313256472 creator A5043073600 @default.
• W4313256472 creator A5045539264 @default.
• W4313256472 creator A5050530209 @default.
• W4313256472 creator A5054182211 @default.
• W4313256472 creator A5056197140 @default.
• W4313256472 creator A5057311746 @default.
• W4313256472 creator A5058232958 @default.
• W4313256472 creator A5058321251 @default.
• W4313256472 creator A5058782853 @default.
• W4313256472 creator A5062383237 @default.
• W4313256472 creator A5065581439 @default.
• W4313256472 creator A5074130054 @default.
• W4313256472 creator A5075894849 @default.
• W4313256472 creator A5076202712 @default.
• W4313256472 creator A5076696174 @default.
• W4313256472 creator A5090124204 @default.
• W4313256472 creator A5090764102 @default.
• W4313256472 date "2023-03-01" @default.
• W4313256472 modified "2023-10-16" @default.
• W4313256472 title "A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)" @default.
• W4313256472 cites W2015943054 @default.
• W4313256472 cites W2107962449 @default.
• W4313256472 cites W2130409622 @default.
• W4313256472 cites W2136866696 @default.
• W4313256472 cites W2143953275 @default.
• W4313256472 cites W2151253787 @default.
• W4313256472 cites W2165480504 @default.
• W4313256472 cites W2345822778 @default.
• W4313256472 cites W2346921980 @default.
• W4313256472 cites W2481516632 @default.
• W4313256472 cites W2919944461 @default.
• W4313256472 cites W3000487074 @default.
• W4313256472 cites W3011169222 @default.
• W4313256472 cites W3112148397 @default.
• W4313256472 cites W3121138383 @default.
• W4313256472 cites W4210976084 @default.
• W4313256472 cites W4211208840 @default.
• W4313256472 cites W4286298195 @default.
• W4313256472 cites W4295828456 @default.
• W4313256472 doi "https://doi.org/10.1016/j.ejca.2022.12.014" @default.
• W4313256472 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36652891" @default.
• W4313256472 hasPublicationYear "2023" @default.
• W4313256472 type Work @default.
• W4313256472 citedByCount "11" @default.
• W4313256472 countsByYear W43132564722023 @default.
• W4313256472 crossrefType "journal-article" @default.
• W4313256472 hasAuthorship W4313256472A5003123255 @default.
• W4313256472 hasAuthorship W4313256472A5010319344 @default.
• W4313256472 hasAuthorship W4313256472A5015481734 @default.
• W4313256472 hasAuthorship W4313256472A5021509769 @default.
• W4313256472 hasAuthorship W4313256472A5022537134 @default.
• W4313256472 hasAuthorship W4313256472A5024065137 @default.
• W4313256472 hasAuthorship W4313256472A5026907664 @default.
• W4313256472 hasAuthorship W4313256472A5032994101 @default.
• W4313256472 hasAuthorship W4313256472A5033152224 @default.
• W4313256472 hasAuthorship W4313256472A5034675205 @default.
• W4313256472 hasAuthorship W4313256472A5036817380 @default.
• W4313256472 hasAuthorship W4313256472A5040581923 @default.
• W4313256472 hasAuthorship W4313256472A5043073600 @default.
• W4313256472 hasAuthorship W4313256472A5045539264 @default.
• W4313256472 hasAuthorship W4313256472A5050530209 @default.
• W4313256472 hasAuthorship W4313256472A5054182211 @default.
• W4313256472 hasAuthorship W4313256472A5056197140 @default.
• W4313256472 hasAuthorship W4313256472A5057311746 @default.
• W4313256472 hasAuthorship W4313256472A5058232958 @default.
• W4313256472 hasAuthorship W4313256472A5058321251 @default.
• W4313256472 hasAuthorship W4313256472A5058782853 @default.
• W4313256472 hasAuthorship W4313256472A5062383237 @default.
• W4313256472 hasAuthorship W4313256472A5065581439 @default.
• W4313256472 hasAuthorship W4313256472A5074130054 @default.
• W4313256472 hasAuthorship W4313256472A5075894849 @default.
• W4313256472 hasAuthorship W4313256472A5076202712 @default.
• W4313256472 hasAuthorship W4313256472A5076696174 @default.
• W4313256472 hasAuthorship W4313256472A5090124204 @default.
• W4313256472 hasAuthorship W4313256472A5090764102 @default.
• W4313256472 hasBestOaLocation W43132564721 @default.
• W4313256472 hasConcept C121608353 @default.
• W4313256472 hasConcept C126322002 @default.
• W4313256472 hasConcept C141071460 @default.
• W4313256472 hasConcept C168563851 @default.
• W4313256472 hasConcept C197934379 @default.
• W4313256472 hasConcept C203092338 @default.
• W4313256472 hasConcept C2776694085 @default.
• W4313256472 hasConcept C2777148230 @default.

• next